Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

78%

7 trials in Phase 3/4

Results Transparency

50%

4 of 8 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3

5(55.6%)

Phase 4

2(22.2%)

N/A

1(11.1%)

Phase 2

1(11.1%)

9Total

Phase 3(5)

Phase 4(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04907474Phase 4Completed

Evaluation of Pupil Dilation Speed With the MAP Dispenser

Role: lead

NCT03942419Phase 3Terminated

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

Role: lead

NCT06217796Phase 4Completed

Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation

Role: lead

NCT05114486Phase 3Completed

Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults

Role: lead

NCT02946125Phase 2Completed

Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil

Role: lead

NCT03751098Phase 3Completed

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

Role: lead

NCT03751631Phase 3Completed

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

Role: lead

NCT04657172Phase 3Completed

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

Role: lead

NCT03480906Not ApplicableCompleted

Eyenovia MiDD Usability Study

Role: lead

All 9 trials loaded